This study establishes a surveillance system to monitor the incidence and risk factors for serious potential adverse events to antiretroviral therapy. We will determine the incidence of clinical adverse events among HIV-infected patients including AIDS and non-AIDS defining malignancies, AIDS defining infections, hepatotoxicity, coronary artery disease, and mortality. The influence of HIV disease stage and concomitant use of antiretrovirals on these outcomes will be determined.